XOMA (NASDAQ:XOMA) Upgraded by StockNews.com to Hold Rating

XOMA (NASDAQ:XOMA) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a report issued on Tuesday.

Separately, HC Wainwright decreased their price objective on shares of XOMA from $123.00 to $104.00 and set a “buy” rating on the stock in a report on Monday, February 3rd.

XOMA Stock Up 3.1 %

Shares of NASDAQ XOMA opened at $26.33 on Tuesday. XOMA has a 52-week low of $19.50 and a 52-week high of $35.00. The company has a debt-to-equity ratio of 1.28, a quick ratio of 7.52 and a current ratio of 7.52. The business has a fifty day moving average of $27.00 and a two-hundred day moving average of $27.98. The stock has a market cap of $310.17 million, a PE ratio of -7.57 and a beta of 0.90.

Insider Activity

In other XOMA news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the business’s stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $26.10, for a total value of $13,069,366.20. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Owen Hughes sold 21,881 shares of XOMA stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $29.95, for a total transaction of $655,335.95. Following the completion of the sale, the chief executive officer now owns 34,979 shares in the company, valued at $1,047,621.05. This trade represents a 38.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 7.20% of the company’s stock.

Hedge Funds Weigh In On XOMA

Hedge funds and other institutional investors have recently made changes to their positions in the company. BNP Paribas Financial Markets raised its stake in XOMA by 95.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock valued at $43,000 after acquiring an additional 795 shares during the period. New York State Common Retirement Fund boosted its holdings in shares of XOMA by 51.2% during the 4th quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company’s stock worth $62,000 after buying an additional 800 shares during the period. Los Angeles Capital Management LLC acquired a new position in XOMA in the 4th quarter valued at about $206,000. Rhumbline Advisers lifted its position in XOMA by 18.1% during the fourth quarter. Rhumbline Advisers now owns 11,065 shares of the biotechnology company’s stock worth $291,000 after acquiring an additional 1,699 shares during the last quarter. Finally, Barclays PLC boosted its holdings in shares of XOMA by 300.7% during the third quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock worth $298,000 after acquiring an additional 8,447 shares during the period. 95.92% of the stock is owned by institutional investors.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.